ADAG News and Press, Adagene Inc. From 02/04/24

2024-02-04 12:00:49 ET More on AbbVie, Johnson & Johnson, etc. AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript AbbVie cit...

2024-01-25 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-21 01:55:00 ET Summary Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in its ...

2024-01-19 09:59:59 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-18 10:00:02 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare had the largest net buying in five months - Goldman Health stocks to watch ...

2024-01-18 08:24:12 ET More on pre-market losers & stocks. Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript Psyence's unit signs deal for up to $10M in funding via issuance of convertible notes Dawson James sees Cytosorbents' Cytosorb as approvabl...

2024-01-17 17:06:02 ET Gainers: Hertz Global Holdings ( HTZ ) +6% . GrabTaxi Holdings ( GRAB ) +4% . R1 RCM ( RCM ) +4% . Arhaus ( ARHS ) +3% . MacroGenics ( MGNX ) +2% . Losers: Adagene ( ADAG ) -8% . biote (...

2024-01-17 08:26:25 ET More on Adagene ADR Seeking Alpha’s Quant Rating on Adagene ADR Historical earnings data for Adagene ADR Financial information for Adagene ADR For further details see: Adagene falls after trial data for cancer therapy

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 ...

- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target - SAN DIEGO an...